Emerging Treatments for Hodgkin’s Lymphoma & The Next Generation of Patients

Abstract

Despite overall survival rates of in the high 80s and 90s, current treatments for Hodgkin’s lymphoma are not yet optimized (Ansell, 2012). High incidence of relapse, secondary malignancies, and long-term toxicity threatens survivors of this disease, especially in the young population. In this study an analysis of current and emerging treatments for various subtypes of Hodgkin’s lymphoma was conducted, including potential side effects and controversies among health care professionals regarding standard of care. The role of clinical trials for prospective treatment advancements was discussed and recommendations concerning the screening and management of survivors were developed. The results in this paper were compiled based on a large review of the current literature and public conferences with experts. This paper summarizes the past, present and future treatments of Hodgkin’s Lymphoma and potential risks that patients face as a result. In order to optimize the treatment of this disease, emerging therapies should aim not only to eliminate cancer cells and tumors, but also to reduce risks of future complications (Xing, 2013).